Annals of Oncology· @Annals_Oncology · X·· 2 天前评分70
正文 · 原文
📢 #ESMO26 concomitant paper - Efficacy and safety of risvutatug rezetecan versus gemcitabine plus docetaxel in relapsed/refractory advanced osteosarcoma: Primary results from the ARTEMIS-011 phase 3 trial.
🔗https://shorturl.at/vwCM2
110 浏览 · 2 赞 · 1 转发 · 0 回复
来源：Annals of Oncology · x.com